A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
D'Haens
Geert
G
University Hospital Gasthuisberg, Leuven, Belgium. geert.dhaens@imelda.be
Sandborn
William J
WJ
Feagan
Brian G
BG
Geboes
Karel
K
Hanauer
Stephen B
SB
Irvine
E Jan
EJ
Lémann
Marc
M
Marteau
Philippe
P
Rutgeerts
Paul
P
Schölmerich
Jurgen
J
Sutherland
Lloyd R
LR
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000473:pathology; D006305:Health Status Indicators; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology*; D015990:Placebo Effect; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D012007:Rectum / Q000473:pathology; D012074:Remission Induction; D012107:Research Design; D012720:Severity of Illness Index; D012812:Sigmoidoscopy / Q000592:standards; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D015415:Biomarkers